SYDNEY--(BUSINESS WIRE)--#clinicaltrials--Australian clinical-stage drug development company, Noxopharm (ASX: NOX), is pleased to announce that a discovery by Weill Cornell Medical College in New York, recently published in the prestigious scientific journal, Nature Immunology, significantly validates the novel DARRT anti-cancer treatment of its drug candidate, Veyonda�, in producing radiation-induced abscopal responses, regarded by many as the ultimate form of treatment for metastatic cancer.

An abscopal response ?� an extraordinarily rare and elusive phenomenon ?� can follow the delivery of a low dose of radiation to a single tumor, triggering an immune response that results in other tumors throughout the body �melting� away in a matter of weeks. Patients who experience a complete abscopal response generally remain in remission for life. The radiation-induced abscopal response is highly prized as being the most cost-effective, least intrusive, and best-tolerated form of immuno-oncology therapy.

The Weill Cornell team identified radiation-induced damage to the cancer cells, and blocking their repair by a process known as autophagy, as fundamental to generating the abscopal response.

The active ingredient in Veyonda, idronoxil, is known to block autophagy.

�For the overwhelming majority of patients, once a cancer spreads from its point of origin and becomes metastatic, the best that current treatments offer is to delay the inevitable,� said Graham Kelly, Noxopharm CEO and managing director. �But the clinical data shows that Veyonda very clearly is boosting the chances of triggering an abscopal response. The Weill Cornell discovery, combined with what we learned from the DARRT-1 study about Veyonda dosing, means we go into the upcoming DARRT-2 study with a high degree of confidence that we are on the edge of a major breakthrough in cancer therapy.�

Noxopharm will now test the ability of Veyonda to induce abscopal effects in a Phase II study involving about 200 patients. DARRT-2 is a Phase II multinational study, currently being planned for a start in early 2021.

About Noxopharm

Noxopharm is a clinical-stage Australian oncology drug development company with offices in Sydney and New York. The company has a primary focus on the development of Veyonda� and is the major shareholder in the non-oncology drug development company, Nyrada Inc.

Contacts

Jane Byram

SCORR Marketing

512-626-2758

[email protected]